Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 5
Submit an article Journal homepage
126
Views
6
CrossRef citations to date
0
Altmetric
Theme: Skin Cancer - Review

Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS

Dionysis Papadatos-Pastos Oncology Outpatient, Lanesborough Wing, St. George’s Hospital, Blackshaw Road, SW17 0QT, UK
,
Adam Januszewski Oncology Outpatient, Lanesborough Wing, St. George’s Hospital, Blackshaw Road, SW17 0QT, UK
&
Angus Dalgleish Oncology Outpatient, Lanesborough Wing, St. George’s Hospital, Blackshaw Road, SW17 0QT, UK. [email protected]
Pages 559-567 | Published online: 10 Jan 2014

References

  • Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 150(2), 179–185 (2004).
  • Kalkanis SN, Kondziolka D, Gaspar LE et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 96(1), 33–43 (2010).
  • Linskey ME, Andrews DW, Asher AL et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 96(1), 45–68 (2010).
  • Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med. 351(10), 998–1012 (2004).
  • Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18(1), 158–166 (2000).
  • Paul MJ, Summers Y, Calvert AH et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 12(2), 175–178 (2002).
  • Ridolfi R, Romanini A, Sileni VC et al. Temozolomide and interferon-α in metastatic melanoma: a Phase II study of the Italian Melanoma Intergroup. Melanoma Res. 14(4), 295–299 (2004).
  • Ready N, Aronson F, Wanebo H, Kennedy T. A low rate of central nervous system progression in a Phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma. Am. J. Clin. Oncol. 28(5), 479–484 (2005).
  • Weber RW, O’Day S, Rose M et al. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-α2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J. Clin. Oncol. 23(35), 8992–9000 (2005).
  • Ron IG, Sarid D, Ryvo L et al. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a Phase II study. Melanoma Res. 16(1), 65–69 (2006).
  • Chiarion-Sileni V, Guida M, Ridolfi L et al.; Italian Melanoma Intergroup (IMI). Central nervous system failure in melanoma patients: results of a randomised, multicentre Phase 3 study of temozolomide- and dacarbazine- based regimens. Br. J. Cancer 104(12), 1816–1821 (2011).
  • Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J. Clin. Oncol. 25(16), 2306–2312 (2007).
  • Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66(9), 1873–1878 (1990).
  • Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J. Clin. Oncol. 22(6), 1118–1125 (2004).
  • Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
  • Potti A, Moazzam N, Tendulkar K, Javed NA, Koch M, Kargas S. Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. Anticancer Res. 23(5A), 4023–4026 (2003).
  • Simonetti O, Lucarini G, Brancorsini D et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 95(9), 1963–1970 (2002).
  • Goydos JS, Gorski DH. Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma. Clin. Cancer Res. 9(16 Pt 1), 5962–5967 (2003).
  • Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19(4), 1207–1225 (2001).
  • Menhert J, McCarthy M, Aziz S et al. VEGF, VEGFR1 and VEGFR2 expression in melanoma. J. Clin. Oncol. 25, Abstract 8520 (2007).
  • Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 19(2), 577–583 (2001).
  • Erhard H, Rietveld FJ, van Altena MC, Bröcker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth Phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res. 7(Suppl. 2), S19–S26 (1997).
  • Lee TH, Avraham HK, Jiang S, Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J. Biol. Chem. 278(7), 5277–5284 (2003).
  • Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284(5422), 1994–1998 (1999).
  • Yano S, Shinohara H, Herbst RS et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 60(17), 4959–4967 (2000).
  • Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542–2550 (2006).
  • Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
  • Varker KA, Biber JE, Kefauver C et al. A randomized Phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol. 14(8), 2367–2376 (2007).
  • González-Cao M, Viteri S, Díaz-Lagares A et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 74(1–2), 12–16 (2008).
  • Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 115(1), 119–127 (2009).
  • Hainsworth JD, Infante JR, Spigel DR et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a Phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 116(17), 4122–4129 (2010).
  • Si L, Chi X, Yuan C et al. Durable response of the triple combination of temozolomide, sorafenib and bevacizumab as second-line therapy for patients with stage IV acralmelanoma. J. Clin. Oncol. 27, Abstract e20010 (2009).
  • Wyman K, Spigel D, Puzanov I et al. A multicenter Phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. J. Clin. Oncol. 25, Abstract 8539 (2007).
  • Munzone E, Testori A, Minchella I et al. A Phase II trial of dacarbazine (DTIC) and bevacizumab in patients with metastatic melanoma. J. Clin. Oncol. 25, Abstract 8579 (2007).
  • Kottschade LA, Suman VJ, Perez DG et al. A randomized Phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775. Cancer 119(3), 586–592 (2012).
  • Kim KB, Sosman JA, Fruehauf JP et al. BEAM: a randomized Phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J. Clin. Oncol. 30(1), 34–41 (2012).
  • Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin. Cancer Res. 16(1), 269–278 (2010).
  • Socinski MA, Langer CJ, Huang JE et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 27(31), 5255–5261 (2009).
  • Decoster L, Neyns B, Vande Broek I et al. Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. J. Clin. Oncol. 28(Suppl. 15), Abstract 8518 (2010).
  • Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95(5), 581–586 (2006).
  • Kim KB, Davies MA, Papadopoulos NE et al. Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. J. Clin. Oncol. 27, Abstract 9026 (2009).
  • Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27(17), 2823–2830 (2009).
  • Amaravadi RK, Schuchter LM, McDermott DF et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin. Cancer Res. 15(24), 7711–7718 (2009).
  • Eisen T, Marais R, Affolter A et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: Phase I and open-label Phase II studies. Br. J. Cancer 105(3), 353–359 (2011).
  • McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol. 26(13), 2178–2185 (2008).
  • Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann. Oncol. 21(5), 1027–1031 (2010).
  • Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N. Engl. J. Med. 365(25), 2439–2441 (2011).
  • Dummer R, Rinderknecht J, Goldinger SM et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J. Clin. Oncol. 29, Abstract 8548 (2011).
  • Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase 1 dose-escalation trial. Lancet 379(9829), 1893–1901 (2012).
  • Kirkwood J, Long G, Trefzer U et al. BREAK-MB: a Phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets). J. Clin. Oncol. 30, Abstract 8501 (2012).
  • Schwartz GK, Robertson S, Shen A et al. A Phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J. Clin. Oncol. 27(Suppl. 15), Abstract 3513 (2009).
  • Sharfman WH, Hodi FS, Lawrence DP et al. Results from the first-in-human (FIH) Phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. J. Clin. Oncol. 29 (Suppl.), Abstract 8508 (2011).
  • Powell SF, Dudek AZ. Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma. J. Clin. Oncol. 27, Abstract e20007 (2009).
  • Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233–5239 (2008).
  • Hong JJ, Rosenberg SA, Dudley ME et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16(19), 4892–4898 (2010).
  • Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
  • Lawrence DP, Hamid O, McDermott DF et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. J. Clin. Oncol. 28, Abstract 8523 (2010).
  • Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, Phase 2 trial. Lancet 13, 459–465 (2012).
  • Di Giacomo AM, Ascierto PA, Pilla L et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm Phase 2 trial. Lancet Oncol. 13(9), 879–886 (2012).
  • Carden CP, Agarwal R, Saran F, Judson IR. Eligibility of patients with brain metastases for Phase I trials: time for a rethink? Lancet Oncol. 9(10), 1012–1017 (2008).
  • Papadatos-Pastos D, Blanco-Codesido M, Carden CP et al. Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from Phase I trials? The Royal Marsden Hospital Drug Development Unit experience. J. Clin. Oncol. 28(Suppl. 15), Abstract 2516 (2010).
  • Tsimberidou AM, Letourneau K, Wen S et al. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin. Cancer Res. 17(12), 4110–4118 (2011).
  • Shintani Y, Higashiyama S, Ohta M et al. Overexpression of ADAM9 in non-small-cell lung cancer correlates with brain metastasis. Cancer Res. 64(12), 4190–4196 (2004).
  • Cattell E, Kelly C, Middleton MR. Brain metastases in melanoma: a European perspective. Semin. Oncol. 29(5), 513–517 (2002).
  • Zagzag D, Goldenberg M, Brem S. Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model. AJR. Am. J. Roentgenol. 153(1), 141–146 (1989).
  • Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 197(4306), 893–895 (1977).
  • Kim SJ, Kim JS, Park ES et al. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 13(3), 286–298 (2011).
  • Xie TX, Huang FJ, Aldape KD et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 66(6), 3188–3196 (2006).
  • Vlodavsky I, Friedmann Y, Elkin M et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5(7), 793–802 (1999).
  • Marchetti D. Specific degradation of subendothelial matrix proteoglycans by brain-metastatic melanoma and brain endothelial cell heparanases. J. Cell. Physiol. 172(3), 334–342 (1997).
  • Colombino M, Capone M, Lissia A et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30(20), 2522–2529 (2012).
  • Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883–892 (2012).
  • Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367(18), 1694–1703 (2012).
  • Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117(2), 227–233 (2012).
  • Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925–931 (2012).
  • Alfaro C, Suarez N, Gonzalez A et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer 100(7), 1111–1119 (2009).
  • Michielsen AJ, Ryan EJ, O’Sullivan JN. Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment. Oncoimmunology 1(8), 1445–1447 (2012).
  • Hodi FS, Sznol M, McDermott DF et al. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). J. Clin. Oncol. 30(Suppl.), Abstract 8507 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.